Ken Griffin Biotechnology

Citadel Advisors LLC

  • $509 Billion
  • Q1 2025

Stock List

Stock Option Type Value Options Held Last Trade Trade History
IMCR
Immunocore Holdings PLC
CALL
$376,000
12.7K
Q1 2025
Reduced 29.12%
RCKT
Rocket Pharmaceuticals, Inc.
CALL
$367,000
55.1K
Q1 2025
Reduced 63.4%
ETNB
89bio, Inc.
PUT
$366,000
50.4K
Q1 2025
Added 7.55%
TERN
Terns Pharmaceuticals, Inc.
PUT
$365,000
133K
Q1 2025
Added 19.59%
GERN
Geron Corp
PUT
$359,000
226K
Q1 2025
Added 59.25%
HRMY
Harmony Biosciences Holdings, Inc.
PUT
$358,000
10.8K
Q1 2025
Reduced 36.97%
QSI
Quantum Si Inc
CALL
$357,000
298K
Q1 2025
New holding
PRTA
Prothena Corp Public LTD CO
CALL
$356,000
28.8K
Q1 2025
Added 115.33%
MLTX
Moon Lake Immunotherapeutics
CALL
$355,000
9.1K
Q1 2025
Reduced 32.39%
DYN
Dyne Therapeutics, Inc.
CALL
$349,000
33.4K
Q1 2025
Added 5.17%
EYPT
Eye Point Pharmaceuticals, Inc.
PUT
$329,000
60.8K
Q1 2025
Reduced 7.33%
TERN
Terns Pharmaceuticals, Inc.
CALL
$327,000
119K
Q1 2025
Added 19.59%
AVXL
Anavex Life Sciences Corp.
PUT
$322,000
37.6K
Q1 2025
Reduced 99.8%
CMPX
Compass Therapeutics, Inc.
PUT
$322,000
170K
Q3 2024
Reduced 76.01%
KYMR
Kymera Therapeutics, Inc.
CALL
$322,000
11.8K
Q1 2025
Reduced 95.72%
MNKD
Mannkind Corp
CALL
$321,000
64K
Q1 2025
Reduced 35.47%
ETNB
89bio, Inc.
CALL
$316,000
43.5K
Q1 2025
Added 7.55%
SANA
Sana Biotechnology, Inc.
CALL
$307,000
183K
Q1 2025
Added 182.25%
XERS
Xeris Biopharma Holdings, Inc.
PUT
$306,000
55.8K
Q1 2025
Added 61.74%
PRTA
Prothena Corp Public LTD CO
PUT
$300,000
24.3K
Q1 2025
Added 115.33%
DYN
Dyne Therapeutics, Inc.
PUT
$299,000
28.6K
Q1 2025
Added 5.17%
WVE
Wave Life Sciences Ltd.
CALL
$294,000
36.5K
Q1 2025
Added 1825.3%
VNDA
Vanda Pharmaceuticals Inc.
PUT
$290,000
63.3K
Q1 2025
Reduced 34.89%
VCEL
Vericel Corp
PUT
$285,000
6.4K
Q1 2025
Reduced 80.49%
AKBA
Akebia Therapeutics, Inc.
PUT
$285,000
149K
Q1 2025
Added 163.86%
SLS
Sellas Life Sciences Group, Inc.
CALL
$285,000
265K
Q1 2025
Reduced 27.98%
LGND
Ligand Pharmaceuticals Inc
CALL
$283,000
2.7K
Q3 2024
Reduced 48.02%
RCUS
Arcus Biosciences, Inc.
PUT
$279,000
35.6K
Q1 2025
Added 4.58%
DNLI
Denali Therapeutics Inc.
CALL
$277,000
20.4K
Q1 2025
Added 40.94%
TPST
Tempest Therapeutics, Inc.
CALL
$272,000
28.4K
Q2 2024
Added 3074300.0%
INMB
Inmune Bio, Inc.
PUT
$271,000
34.8K
Q1 2025
Added 94.48%
OMER
Omeros Corp
CALL
$271,000
33K
Q1 2025
Added 137.59%
CADL
Candel Therapeutics, Inc.
PUT
$270,000
47.9K
Q1 2025
Reduced 96.69%
NUVB
Nuvation Bio Inc.
PUT
$270,000
154K
Q1 2025
Reduced 3.31%
ABSI
Absci Corp
CALL
$268,000
107K
Q1 2025
Added 146.38%
PHAT
Phathom Pharmaceuticals, Inc.
CALL
$263,000
42.1K
Q1 2025
Added 149.59%
RCUS
Arcus Biosciences, Inc.
CALL
$260,000
33.2K
Q1 2025
Added 4.58%
MGTX
Meira G Tx Holdings PLC
PUT
$260,000
38.4K
Q1 2025
Reduced 78.54%
XENE
Xenon Pharmaceuticals Inc.
CALL
$258,000
7.7K
Q1 2025
Added 109.92%
CNTA
Centessa Pharmaceuticals PLC
PUT
$247,000
17.2K
Q1 2025
Added 12.96%
CNTA
Centessa Pharmaceuticals PLC
CALL
$245,000
17.1K
Q1 2025
Added 12.96%
RGNX
Regenxbio Inc.
PUT
$245,000
34.3K
Q1 2025
Added 75.52%
HUMA
Humacyte, Inc.
PUT
$244,000
143K
Q1 2025
Added 1598.28%
SNDX
Syndax Pharmaceuticals Inc
PUT
$243,000
19.8K
Q1 2025
Added 167.47%
SGMO
Sangamo Therapeutics, Inc
PUT
$237,000
360K
Q1 2025
Reduced 52.65%
AMRN
Amarin Corp Plcuk
PUT
$236,000
26.4K
Q4 2024
Added 32.33%
BCYC
Bicycle Therapeutics PLC
PUT
$235,000
27.7K
Q1 2025
Reduced 9.82%
PHAT
Phathom Pharmaceuticals, Inc.
PUT
$230,000
36.7K
Q1 2025
Added 149.59%
ARCT
Arcturus Therapeutics Holdings Inc.
CALL
$228,000
21.6K
Q1 2025
Reduced 53.62%
Filter Shares Options
Ken Griffin

Ken Griffin

Ken Griffin is the founder and CEO of Citadel Advisors, a successful investment firm that uses technology and data-driven approaches to investing. Griffin is known for his expertise in quantitative investing and his innovative approach to investing. He has generated strong returns for his clients over the long term.
Track Ken Griffin's portfolio
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email